124 related articles for article (PubMed ID: 21950422)
1. Lipocalin-2 is associated with modulation of disease phenotype in a patient with concurrent JAK2-V617F and BCR-ABL mutation.
Nadarajan VS; Ang CH; Bee PC
Eur J Haematol; 2012 Feb; 88(2):175-8. PubMed ID: 21950422
[TBL] [Abstract][Full Text] [Related]
2. A man with concomitant polycythaemia vera and chronic myeloid leukemia: the dynamics of the two disorders.
Bee PC; Gan GG; Nadarajan VS; Latiff NA; Menaka N
Int J Hematol; 2010 Jan; 91(1):136-9. PubMed ID: 20047097
[TBL] [Abstract][Full Text] [Related]
3. BCR-ABL but not JAK2 V617F inhibits erythropoiesis through the Ras signal by inducing p21CIP1/WAF1.
Tokunaga M; Ezoe S; Tanaka H; Satoh Y; Fukushima K; Matsui K; Shibata M; Tanimura A; Oritani K; Matsumura I; Kanakura Y
J Biol Chem; 2010 Oct; 285(41):31774-82. PubMed ID: 20663870
[TBL] [Abstract][Full Text] [Related]
4. Feasibility of Qualitative Testing of BCR-ABL and JAK2 V617F in Suspected Myeloproliperative Neoplasm (MPN) Using RT-PCR Reversed Dot Blot Hybridization (RT-PCR RDB).
Masykura N; Habibah U; Selasih SF; Gani S; Irawan C; Somoastro S; Handoyo Utomo AR
Clin Lymphoma Myeloma Leuk; 2019 Apr; 19(4):220-227. PubMed ID: 30772299
[TBL] [Abstract][Full Text] [Related]
5. Insights into JAK2-V617F mutation in CML.
Bocchia M; Vannucchi AM; Gozzetti A; Guglielmelli P; Poli G; Crupi R; Defina M; Bosi A; Francesco L
Lancet Oncol; 2007 Oct; 8(10):864-6. PubMed ID: 17913657
[No Abstract] [Full Text] [Related]
6. Neutrophil gelatinase-associated lipocalin expression in chronic myeloid leukemia.
Villalva C; Sorel N; Bonnet ML; Guilhot J; Mayeur-Rousse C; Guilhot F; Chomel JC; Turhan AG
Leuk Lymphoma; 2008 May; 49(5):984-8. PubMed ID: 18464118
[TBL] [Abstract][Full Text] [Related]
7. Thrombocytosis and STAT5 activation in chronic myelogenous leukaemia are not associated with JAK2 V617F or calreticulin mutations.
Turakhia SK; Murugesan G; Cotta CV; Theil KS
J Clin Pathol; 2016 Aug; 69(8):713-9. PubMed ID: 26754830
[TBL] [Abstract][Full Text] [Related]
8. Chronic myeloid leukemia patient with co-occurrence of BCR-ABL junction and JAK2 V617F mutation.
Xu W; Chen B; Tong X
Int J Hematol; 2014 Jan; 99(1):87-90. PubMed ID: 24293258
[TBL] [Abstract][Full Text] [Related]
9. JAK2-V617F and BCR-ABL--double jeopardy?
Krämer A
Leuk Res; 2008 Oct; 32(10):1489-90. PubMed ID: 18439674
[No Abstract] [Full Text] [Related]
10. Clinical and laboratory relevance of JAK2 V617F and BCR-ABL co-existence in Philadelphia positive CML patients.
Ahmad N; Qayum S; Jameel A; Ali A; Siraj S; Ali J; Yousafzai YM
Pak J Pharm Sci; 2021 Nov; 34(6(Supplementary)):2289-2295. PubMed ID: 35039265
[TBL] [Abstract][Full Text] [Related]
11. Lipocalin 2 is required for BCR-ABL-induced tumorigenesis.
Leng X; Lin H; Ding T; Wang Y; Wu Y; Klumpp S; Sun T; Zhou Y; Monaco P; Belmont J; Aderem A; Akira S; Strong R; Arlinghaus R
Oncogene; 2008 Oct; 27(47):6110-9. PubMed ID: 18663364
[TBL] [Abstract][Full Text] [Related]
12. Insights into JAK2-V617F mutation in CML.
Büsche G; Hussein K; Bock O; Kreipe H
Lancet Oncol; 2007 Oct; 8(10):863-4. PubMed ID: 17913656
[No Abstract] [Full Text] [Related]
13. AHI-1 interacts with BCR-ABL and modulates BCR-ABL transforming activity and imatinib response of CML stem/progenitor cells.
Zhou LL; Zhao Y; Ringrose A; DeGeer D; Kennah E; Lin AE; Sheng G; Li XJ; Turhan A; Jiang X
J Exp Med; 2008 Oct; 205(11):2657-71. PubMed ID: 18936234
[TBL] [Abstract][Full Text] [Related]
14. [BCR-ABL1-positive chronic myeloid leukemia emerging in a patient with secondary myelofibrosis harboring the JAK2-V617F mutation].
Amemiya A; Ito Y; Ishibashi Y; Saito Y; Katagiri S; Suguro T; Asano M; Yoshizawa S; Akahane D; Tanaka Y; Fujimoto H; Okabe S; Gotoh M; Tauchi T; Ohyashiki K
Rinsho Ketsueki; 2017; 58(4):298-302. PubMed ID: 28484156
[TBL] [Abstract][Full Text] [Related]
15. [Correlation of lipocalin-2 and its receptor expressions with preeclampsia].
Cao WH; Chen WP; Li J; Ye YH
Zhonghua Fu Chan Ke Za Zhi; 2012 Jun; 47(6):418-21. PubMed ID: 22932106
[TBL] [Abstract][Full Text] [Related]
16. Simultaneous detection of JAK2 V617F mutation and Bcr-Abl translocation in a patient with chronic myelogenous leukemia.
de Conchon MRM; Costa JL; Novaes MMY; Dorlhiac-Llacer PE; de Alencar Fischer Chamone D; Bendit I
Int J Hematol; 2008 Sep; 88(2):243-245. PubMed ID: 18626727
[No Abstract] [Full Text] [Related]
17. BCR-ABL activates STAT3 via JAK and MEK pathways in human cells.
Coppo P; Flamant S; De Mas V; Jarrier P; Guillier M; Bonnet ML; Lacout C; Guilhot F; Vainchenker W; Turhan AG
Br J Haematol; 2006 Jul; 134(2):171-9. PubMed ID: 16846476
[TBL] [Abstract][Full Text] [Related]
18. The incidence of co-existing BCR-ABL1 and JAK2 V617F rearrangements: implications for molecular diagnostics.
McCarron SL; Haslam K; Crampe M; Langabeer SE
Lab Hematol; 2012 Dec; 18(4):20-1. PubMed ID: 23253862
[No Abstract] [Full Text] [Related]
19. Concurrent JAK2-Positive Myeloproliferative Disorder and Chronic Myelogenous Leukemia: A Novel Entity? A Case Report With Review of the Literature.
Bader G; Dreiling B
J Investig Med High Impact Case Rep; 2019; 7():2324709619832322. PubMed ID: 30803277
[TBL] [Abstract][Full Text] [Related]
20. Concomitant BCR-ABL1 translocation and JAK2(V617F) mutation in three patients with myeloproliferative neoplasms.
Hummel JM; Kletecka MC; Sanks JK; Chiselite MD; Roulston D; Smith LB; Czuchlewski DR; Elenitoba-Johnson KS; Lim MS
Diagn Mol Pathol; 2012 Sep; 21(3):176-83. PubMed ID: 22847163
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
